Graphite Bio doses first patient with nula-cel; Q3 net loss $24.7M; cash runway into Q4 2024

LENZ Therapeutics, Inc.

2022-Q3 EPS reported -$1.40

Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023.
Q3 net loss $24.7M ($0.45 per share); R&D expenses $18.3M, G&A $7.9M.
Cash, equivalents and investments $305.1M as of Sep 30, 2022; runway into Q4 2024.
Entered strategic manufacturing partnership with WuXi Advanced Therapies for nula-cel.
Two abstracts accepted for ASH 2022; hired Darren Hart as SVP of development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

LENZ Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $24.7 million, or $0.45 per basic and diluted share, EPS $0.45 per basic and diluted share.

Period: the quarter ended September 30, 2022
Net income: Net loss was $24.7 million, or $0.45 per basic and diluted share
EPS: $0.45 per basic and diluted share
Result: reported results

Exact text from the filing

Graphite Bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.